BHC Stock Overview
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Bausch Health Companies Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$9.38 |
52 Week High | US$10.15 |
52 Week Low | US$5.57 |
Beta | 0.83 |
1 Month Change | 10.22% |
3 Month Change | 24.57% |
1 Year Change | 23.26% |
3 Year Change | -71.54% |
5 Year Change | -61.14% |
Change since IPO | 1,776.00% |
Recent News & Updates
Recent updates
Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation
Feb 24Bausch Health: $20bn Debt Is A Mighty Elephant In The Room
Nov 30Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?
Nov 01Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics
Sep 24Is Bausch Health Companies (NYSE:BHC) A Risky Investment?
Jul 24Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes
Jul 06What To Do After Bausch Health Stock Plunged By Nearly 9% Again
Jun 07Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt
Apr 18Bausch Health: A Basket Case Of A Business Only A Hedge Fund Can Bail Out
Dec 30Bausch Health acne lotion Arazlo available in Canada under public drug plans
Dec 22Bausch Health: Things To Consider Before Investing
Dec 11Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues
Nov 10Bausch Health Companies Q3 2022 Earnings Preview
Nov 02Bausch Health: Long-Term Need To Place Stops For Protection
Sep 28Bausch Health Companies: Equity Stub Would Benefit From Ambitious Spinoff
Sep 21Bausch Health sheds 10% as FDA grants tentative approval for Xifaxan generic
Sep 08Bausch Health begin offers to exchange debt up to $4B
Aug 31Bausch Health Stock Down 11%: Now What?
Aug 09Bausch Health: How To Price The Calamities
Jul 31Bausch Health: Uncertain, Far From Healthy, But Potentially Lucrative
Jul 18Bausch Health Stock Soared By 20%: What To Do Now
Jun 27Bausch Health Companies: 2022's Most Compelling Special Situation
Jun 10Shareholder Returns
BHC | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 2.9% | -0.3% | -0.1% |
1Y | 23.3% | 22.5% | 28.4% |
Return vs Industry: BHC matched the US Pharmaceuticals industry which returned 22.5% over the past year.
Return vs Market: BHC underperformed the US Market which returned 28.4% over the past year.
Price Volatility
BHC volatility | |
---|---|
BHC Average Weekly Movement | 5.0% |
Pharmaceuticals Industry Average Movement | 9.6% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BHC has not had significant price volatility in the past 3 months.
Volatility Over Time: BHC's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 20,270 | Tom Appio | https://www.bauschhealth.com |
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
Bausch Health Companies Inc. Fundamentals Summary
BHC fundamental statistics | |
---|---|
Market cap | US$3.43b |
Earnings (TTM) | -US$592.00m |
Revenue (TTM) | US$8.76b |
0.4x
P/S Ratio-5.8x
P/E RatioIs BHC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BHC income statement (TTM) | |
---|---|
Revenue | US$8.76b |
Cost of Revenue | US$2.56b |
Gross Profit | US$6.20b |
Other Expenses | US$6.79b |
Earnings | -US$592.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.62 |
Gross Margin | 70.78% |
Net Profit Margin | -6.76% |
Debt/Equity Ratio | -27,302.4% |
How did BHC perform over the long term?
See historical performance and comparison